Austar Lifesciences H1 profit drops on higher R&D spending

Austar Lifesciences

25/08/2026 13:44

Overview
China life sciences solutions firm's H1 revenue rose 12% yr/yr
Profit attributable to owners fell sharply, with EPS down to RMB 0.02 from RMB 0.05
Gross profit margin declined to 18.6% from 21.0% yr/yr

Outlook
Company did not provide specific guidance or outlook for future periods

Result Drivers
HIGHER OPERATING EXPENSES - Increased selling, marketing, and administrative expenses weighed on profitability
RESEARCH AND DEVELOPMENT SPENDING - Research and development expenses rose to RMB 17,362, up from RMB 16,480

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 744.48 mln
 

Reuters Recommended Reads
Aug 24 - China's RemeGen H1 revenue soars on drug sales, AbbVie deal
Aug 24 - China's Asymchem H1 revenue rises on strength in emerging businesses
Aug 24 - China's Nanjing Sinolife H1 profit falls on higher selling and distribution expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)